172 related articles for article (PubMed ID: 25343550)
21. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
[TBL] [Abstract][Full Text] [Related]
22. Serotonin increases phosphorylation of synaptic 4EBP through TOR, but eukaryotic initiation factor 4E levels do not limit somatic cap-dependent translation in aplysia neurons.
Carroll M; Dyer J; Sossin WS
Mol Cell Biol; 2006 Nov; 26(22):8586-98. PubMed ID: 16982686
[TBL] [Abstract][Full Text] [Related]
23. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
24. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
25. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
[TBL] [Abstract][Full Text] [Related]
26. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
27. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.
Hsieh AC; Costa M; Zollo O; Davis C; Feldman ME; Testa JR; Meyuhas O; Shokat KM; Ruggero D
Cancer Cell; 2010 Mar; 17(3):249-61. PubMed ID: 20227039
[TBL] [Abstract][Full Text] [Related]
28. Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells.
Pola C; Formenti SC; Schneider RJ
Cancer Res; 2013 Jul; 73(14):4571-8. PubMed ID: 23722547
[TBL] [Abstract][Full Text] [Related]
29. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ
J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449
[TBL] [Abstract][Full Text] [Related]
30. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas.
Kouvaraki MA; Liakou C; Paraschi A; Dimas K; Patsouris E; Tseleni-Balafouta S; Rassidakis GZ; Moraitis D
Surgery; 2011 Dec; 150(6):1258-65. PubMed ID: 22136849
[TBL] [Abstract][Full Text] [Related]
31. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
[TBL] [Abstract][Full Text] [Related]
32. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.
Yan J; Zhou H; Kong L; Zhang J; Zhao Q; Li Y
Cancer Chemother Pharmacol; 2013 Oct; 72(4):799-808. PubMed ID: 23934262
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.
Wang R; Geng J; Wang JH; Chu XY; Geng HC; Chen LB
Lung Cancer; 2009 Nov; 66(2):237-44. PubMed ID: 19261348
[TBL] [Abstract][Full Text] [Related]
34. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
35. Increased milk protein synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of rapamycin (mTOR)C1-dependent and independent cell signaling.
Sciascia Q; Pacheco D; McCoard SA
J Dairy Sci; 2013 Apr; 96(4):2327-2338. PubMed ID: 23462168
[TBL] [Abstract][Full Text] [Related]
36. The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model.
Pons B; Peg V; Vázquez-Sánchez MA; López-Vicente L; Argelaguet E; Coch L; Martínez A; Hernández-Losa J; Armengol G; Ramon Y Cajal S
Int J Oncol; 2011 Nov; 39(5):1337-45. PubMed ID: 21750861
[TBL] [Abstract][Full Text] [Related]
37. Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3.
Tsukumo Y; Alain T; Fonseca BD; Nadon R; Sonenberg N
Nat Commun; 2016 Jun; 7():11776. PubMed ID: 27319316
[TBL] [Abstract][Full Text] [Related]
38. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.
Fingar DC; Salama S; Tsou C; Harlow E; Blenis J
Genes Dev; 2002 Jun; 16(12):1472-87. PubMed ID: 12080086
[TBL] [Abstract][Full Text] [Related]
39. 4E-binding protein phosphorylation and eukaryotic initiation factor-4E release are required for airway smooth muscle hypertrophy.
Zhou L; Goldsmith AM; Bentley JK; Jia Y; Rodriguez ML; Abe MK; Fingar DC; Hershenson MB
Am J Respir Cell Mol Biol; 2005 Aug; 33(2):195-202. PubMed ID: 15901615
[TBL] [Abstract][Full Text] [Related]
40. Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.
Zakaria C; Sean P; Hoang HD; Leroux LP; Watson M; Workenhe ST; Hearnden J; Pearl D; Truong VT; Robichaud N; Yanagiya A; Tahmasebi S; Jafarnejad SM; Jia JJ; Pelin A; Diallo JS; Le Boeuf F; Bell JC; Mossman KL; Graber TE; Jaramillo M; Sonenberg N; Alain T
PLoS Pathog; 2018 Aug; 14(8):e1007264. PubMed ID: 30138450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
